Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
6(38%)
Results Posted
25%(1 trials)

Phase Distribution

Ph not_applicable
6
38%
Ph phase_1
2
13%
Ph phase_2
5
31%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
5(38.5%)
N/ANon-phased studies
6(46.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

16

all time

Status Distribution
Active(7)
Completed(4)
Terminated(1)
Other(4)

Detailed Status

Completed4
unknown4
Recruiting3
Active, not recruiting3
Enrolling by invitation1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
6
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (15.4%)
Phase 25 (38.5%)
N/A6 (46.2%)

Trials by Status

completed425%
enrolling_by_invitation16%
recruiting319%
active_not_recruiting319%
unknown425%
withdrawn16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT05653011

Predictors of Prognosis in IBD Patients

Recruiting
NCT03641313Phase 2

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Active Not Recruiting
NCT05078866Phase 1

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Active Not Recruiting
NCT05408728

Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

Enrolling By Invitation
NCT04929392Phase 2

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Active Not Recruiting
NCT06780787Phase 2

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Recruiting
NCT03809728Not Applicable

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

Recruiting
NCT00602602Phase 2

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

Completed
NCT03419936

Distribution of Helicobacter Pylori After Gastrectomy

Unknown
NCT00987857Not Applicable

Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus

Unknown
NCT01282853Not Applicable

Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding

Completed
NCT00019201Not Applicable

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

Completed
NCT00081003Not Applicable

Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer

Completed
NCT00960427Phase 1

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

Withdrawn
NCT00751660Not Applicable

Screening Methods in Finding Lung Cancer Early in Current or Former Smokers

Unknown
NCT00659113Phase 2

S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery

Unknown

All 16 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
16